NO20040153L - Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes - Google Patents

Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes

Info

Publication number
NO20040153L
NO20040153L NO20040153A NO20040153A NO20040153L NO 20040153 L NO20040153 L NO 20040153L NO 20040153 A NO20040153 A NO 20040153A NO 20040153 A NO20040153 A NO 20040153A NO 20040153 L NO20040153 L NO 20040153L
Authority
NO
Norway
Prior art keywords
treatment
pharmaceutical combination
diabetes
prophylaxis
synergistic pharmaceutical
Prior art date
Application number
NO20040153A
Other languages
English (en)
Inventor
Gyorgy Rabloczky
Zoltan Szilvassy
Nagy Peter Literati
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Publication of NO20040153L publication Critical patent/NO20040153L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
NO20040153A 2001-07-17 2004-01-13 Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes NO20040153L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére
PCT/HU2002/000067 WO2003007951A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Publications (1)

Publication Number Publication Date
NO20040153L true NO20040153L (no) 2004-03-16

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040153A NO20040153L (no) 2001-07-17 2004-01-13 Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes

Country Status (21)

Country Link
US (2) US7635674B2 (no)
EP (1) EP1408966B1 (no)
JP (1) JP4598390B2 (no)
KR (1) KR100920560B1 (no)
CN (1) CN1270713C (no)
AT (1) ATE386523T1 (no)
AU (1) AU2002354884B2 (no)
BR (1) BR0210744A (no)
CA (2) CA2682251A1 (no)
CY (1) CY1107939T1 (no)
DE (1) DE60225143T2 (no)
DK (1) DK1408966T3 (no)
ES (1) ES2300460T3 (no)
IL (2) IL159412A0 (no)
MX (1) MXPA04000324A (no)
NO (1) NO20040153L (no)
NZ (1) NZ531155A (no)
PL (1) PL205826B1 (no)
PT (1) PT1408966E (no)
RU (1) RU2311907C2 (no)
WO (1) WO2003007951A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090036355A1 (en) * 2004-10-13 2009-02-05 Sanjay Bhanot Antisense Modulation of PTP1B Expression
ES2355680T3 (es) * 2006-11-02 2011-03-30 N-Gene Research Laboratories Inc. Reducción del sobrepeso o de la obesidad.
ZA200902761B (en) * 2006-11-02 2010-07-28 N Gene Res Lab Inc A pharmaceutical composition having antipsychotic, antidepressant or antiepileptic activity with reduced side effect
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7753949B2 (en) * 2007-02-23 2010-07-13 The Trustees Of The University Of Pennsylvania Valve prosthesis systems and methods
NZ583346A (en) 2007-07-19 2012-02-24 Takeda Pharmaceutical Solid preparation comprising alogliptin and metformin hydrochloride
US8277845B2 (en) 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
US8658783B2 (en) 2011-04-13 2014-02-25 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
IL271443B2 (en) 2017-06-30 2024-01-01 Univ California Preparations and methods for regulating hair growth
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
JP2023532840A (ja) * 2020-05-27 2023-08-01 コーセプト セラピューティクス， インコーポレイテッド グルココルチコイド受容体モジュレーターレラコリラントおよびｃｙｐ２ｃ９基質の併用投与

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Also Published As

Publication number Publication date
CY1107939T1 (el) 2013-09-04
RU2311907C2 (ru) 2007-12-10
US20100048627A1 (en) 2010-02-25
AU2002354884A2 (en) 2003-03-03
US20070015687A1 (en) 2007-01-18
NZ531155A (en) 2005-07-29
ES2300460T3 (es) 2008-06-16
CA2452558C (en) 2009-12-22
WO2003007951A1 (en) 2003-01-30
US7635674B2 (en) 2009-12-22
IL159412A0 (en) 2004-06-01
JP2004537550A (ja) 2004-12-16
KR100920560B1 (ko) 2009-10-08
MXPA04000324A (es) 2004-07-23
BR0210744A (pt) 2004-07-20
IL159412A (en) 2009-09-22
KR20040029371A (ko) 2004-04-06
DE60225143T2 (de) 2009-02-12
PL364662A1 (en) 2004-12-13
ATE386523T1 (de) 2008-03-15
CA2682251A1 (en) 2003-01-30
EP1408966B1 (en) 2008-02-20
US8048873B2 (en) 2011-11-01
DK1408966T3 (da) 2008-06-16
CA2452558A1 (en) 2003-01-30
RU2004105149A (ru) 2005-04-20
CN1531433A (zh) 2004-09-22
PT1408966E (pt) 2008-05-02
JP4598390B2 (ja) 2010-12-15
AU2002354884B2 (en) 2007-10-18
EP1408966A1 (en) 2004-04-21
DE60225143D1 (de) 2008-04-03
CN1270713C (zh) 2006-08-23
PL205826B1 (pl) 2010-05-31

Similar Documents

Publication Publication Date Title
NO20040153L (no) Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
ES2191048T3 (es) Derivados de oxazolidinona y compuestos farmaceuticos que los contienen.
NO20006221L (no) Fremgangsmåte for bekjempelse av skadedyr
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
NO20032488D0 (no) Orto-substituerte nitrogen-inneholdende bisarylforbindelser anvendt som kaliumkanalinhibitorer
HUP0102260A2 (hu) ACE inhibitorokat tartalmazó kompozíciók stabilizálása magnézium-oxid alkalmazásával
HUP0103781A2 (hu) Megismerési képesség javítására szolgáló gyógyszerkészítmények, melyek atipikus antipszihotikus szer és acetilkolinészteráz inhibitor kombinációját tartalmazzák
WO2002094796A3 (en) Benzo[g]quinoxaline derivatives as effective compounds against infectious diseases
EA199901012A1 (ru) Фармацевтические композиции на основе тизоксанида и нитазоксанида
DE60005517D1 (de) Kaliumkanal-blockierende mittel
WO2002072581A3 (en) Pyrazolopyriadine derivatives
SE9904128D0 (sv) Novel compounds
RS20050776A (en) A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment diabetes
RS4904A (en) Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
UA81608C2 (ru) Синергическая фармацевтическая комбинация для профилактики или лечения диабета
TW200640464A (en) Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient
ES2179667T3 (es) Nuevas formulaciones inyectables que contienen ramoplanina.
WO2002083641A3 (en) Amino-aza-cyclohexanes for the treatment of malaria
EP1464636A4 (en) NEW SUBSTANCE WITH ANTITUM EFFECT / INFLAMMATORY EFFECT
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application